Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer

Breast Cancer Research and Treatment

Volumn 147, Issue 2, 2014, Pages 283-293

  Madden, Julie M ^a   Mueller, Kelly L ^a   Bollig Fischer, Aliccia ^a   Stemmer, Paul ^a   Mattingly, Raymond R ^a,b   Boerner, Julie L ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

EGFR; mTOR; Translation initiation; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EIF-4B; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INITIATION FACTOR; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTORS; FEMALE; HEK293 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929995079     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3102-8     Document Type: Article

References (34)

1. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010–8018. doi:10.1158/1078-0432.CCR-08-1208
2. Santana-Davila RPE (2010) Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 3:42
3. Chacon RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12(Suppl 2):S3. doi:10.1186/bcr2574
4. Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O’Regan RM (2011) Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther 10(8):1460–1469. doi:10.1158/1535-7163.MCT-10-0925
5. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7(9):493–507. doi:10.1038/nrclinonc.2010.97
6. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21):2615–2623. doi:10.1200/JCO.2010.34.5579
7. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78(5):460–468. doi:10.1016/j.bcp.2009.04.033
8. Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL (2012) EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK. Transl oncol 5(5):327–334
9. Brian Rini SK, Kirkpatrick Peter (2007) Temsirolimus. Nat Rev Drug Discovery 6:599–600
10. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 19(8):919–930. doi:10.1517/13543784.2010.499121
11. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681. doi:10.1124/pr.58.3.10
12. Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10(4):254–266. doi:10.1038/nrc2824
13. Loreni F, Mancino M, Biffo S (2013) Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogene. doi:10.1038/onc.2013.153
14. van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, Hershey JW, Burgering BM, Calkhoven CF, Coffer PJ (2009) AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28(1):95–106. doi:10.1038/onc.2008.367
15. Raught B, Peiretti F, Gingras AC, Livingstone M, Shahbazian D, Mayeur GL, Polakiewicz RD, Sonenberg N, Hershey JW (2004) Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23(8):1761–1769. doi:10.1038/sj.emboj.7600193
16. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282(19):14056–14064. doi:10.1074/jbc.M700906200
17. Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913–963. doi:10.1146/annurev.biochem.68.1.913
18. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N (2010) eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 9(20):4106–4109
19. Merrick WC (2004) Cap-dependent and cap-independent translation in eukaryotic systems. Gene 332:1–11. doi:10.1016/j.gene.2004.02.051
20. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25(12):2781–2791. doi:10.1038/sj.emboj.7601166
21. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332–337. doi:10.1038/nature02369
22. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA (2006) Short RNAs repress translation after initiation in mammalian cells. Mol Cell 21(4):533–542. doi:10.1016/j.molcel.2006.01.031
23. Hawk NROR (2010) Treatment of triple-negative breast cancer. Community Oncology 7:328–332
24. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98(5):923–930. doi:10.1038/sj.bjc.6604269
25. O’Regan R, Hawk NN (2011) mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 15(7):859–872. doi:10.1517/14728222.2011.575362
26. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345(6275):544–547. doi:10.1038/345544a0
27. Montanaro L, Trere D, Derenzini M (2012) Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. Biochim Biophys Acta 1825(1):101–110. doi:10.1016/j.bbcan.2011.10.006
28. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA, Pelletier J, Ratsch G, Wendel HG (2014) RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. doi:10.1038/nature13485
29. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Desaubry L, Robert C, Vagner S (2014) eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. doi:10.1038/nature13572
30. Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA (2005) The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65(8):3108–3116. doi:10.1158/0008-5472.CAN-04-3151
31. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988–1004. doi:10.1038/nrd1902
32. Romeo Y, Roux PP (2011) Paving the way for targeting RSK in cancer. Expert Opin Ther Targets 15(1):5–9. doi:10.1517/14728222.2010.531014
33. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74(20):5383–5392
34. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75(17):4646–4658